What determines skin sensitization potency-myths, maybes and realities. Part 1. The 500 molecular weight cut-off
One article on PainSci cites Roberts 2013: Does Epsom Salt Work?
original abstract †Abstracts here may not perfectly match originals, for a variety of technical and practical reasons. Some abstacts are truncated for my purposes here, if they are particularly long-winded and unhelpful. I occasionally add clarifying notes. And I make some minor corrections.
BACKGROUND: It is widely accepted that there is a molecular weight (MW) cut-off of 500, such that single chemicals with MWs higher than 500 cannot be skin sensitizers. If true, this could serve as a useful principle for designing non-sensitizing chemicals.
OBJECTIVES: To assess whether the 500 MW cut-off is a myth or a reality.
METHODS: A database of 699 chemicals tested for skin sensitization in guinea pigs or mice was analysed to establish the number of tested chemicals with MW> 500, and to establish whether any of these were sensitizers.
RESULTS: Only 13 (2%) of the 699 chemicals in the database have MW> 500. Of the 13 tested compounds with MW> 500 in the database, five are sensitizers and eight are non-sensitizers.
CONCLUSIONS: The 500 MW cut-off for skin sensitization is a myth, probably derived from the widespread misconception that ability to efficiently penetrate the stratum corneum is a key determinant of sensitization potency. The scarcity of sensitizers with MW> 500 simply reflects the general scarcity of chemicals with MW> 500.
related content
- “The 500 Dalton rule for the skin penetration of chemical compounds and drugs,” J D Bos and M M Meinardi, Exp Dermatol, 2000.
- “Determinants of skin sensitisation potential,” David W Roberts and Aynur O Aptula, J Appl Toxicol, 2008.
This page is part of the PainScience BIBLIOGRAPHY, which contains plain language summaries of thousands of scientific papers & others sources. It’s like a highly specialized blog. A few highlights:
- A double-blinded randomised controlled study of the value of sequential intravenous and oral magnesium therapy in patients with chronic low back pain with a neuropathic component. Yousef 2013 Anaesthesia.
- Is Neck Posture Subgroup in Late Adolescence a Risk Factor for Persistent Neck Pain in Young Adults? A Prospective Study. Richards 2021 Phys Ther.
- Photobiomodulation therapy is not better than placebo in patients with chronic nonspecific low back pain: a randomised placebo-controlled trial. Guimarães 2021 Pain.
- No effect of creatine monohydrate supplementation on inflammatory and cartilage degradation biomarkers in individuals with knee osteoarthritis. Cornish 2018 Nutr Res.
- The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Bebee 2021 Med J Aust.